GLP-1 RA Adherence: 1-Year Drop-Off Rates Explained
- This article details a study examining why people stop taking semaglutide (a GLP-1 RA drug like Ozempic and Wegovy) for weight loss.Here's a breakdown of the key findings:
- * Cost is a Major Barrier: Medicare and Medicaid currently don't cover these drugs for weight loss, leading to significant out-of-pocket expenses (around $2350-$2360 for the lowest dose...
- In essence, the study highlights that while GLP-1 RA drugs can be effective for weight loss, access and affordability, along with managing side effects, are significant challenges to...
Summary of GLP-1 RA Discontinuation Study
This article details a study examining why people stop taking semaglutide (a GLP-1 RA drug like Ozempic and Wegovy) for weight loss.Here’s a breakdown of the key findings:
key Points:
* Cost is a Major Barrier: Medicare and Medicaid currently don’t cover these drugs for weight loss, leading to significant out-of-pocket expenses (around $2350-$2360 for the lowest dose as of June 2025). Higher income individuals are far more likely to continue using the medication.
* High Discontinuation Rate: Over half (50%) of first-time users in Denmark stopped taking semaglutide within one year of starting. Specifically:
* 18% stopped after 3 months
* 31% stopped after 6 months
* 42% stopped after 9 months
* Demographic Factors:
* Age: Younger adults (18-29) were 48% more likely to discontinue than those aged 45-59.
* Income: Those in low-income areas were 14% more likely to discontinue than those in higher-income areas.
* Medical History & Side Effects:
* Gastrointestinal Issues: Patients with a history of gastrointestinal medication were 9% more likely to stop due to adverse effects like nausea,vomiting,and diarrhea.
* Psychiatric & Chronic Conditions: Those with a history of psychiatric medication were 12% more likely to discontinue, and those with cardiovascular disease or other chronic conditions were 10% more likely.
* Dosage & Expectations: Lower doses are more tolerable in terms of side effects,but result in less weight loss. Increasing the dosage to achieve better results can lead to unbearable side effects and discontinuation.
* Overall: Success with the drug (weight loss and tolerating side effects) is linked to continued use. The treatment isn’t simple and requires resilience and compliance.
In essence, the study highlights that while GLP-1 RA drugs can be effective for weight loss, access and affordability, along with managing side effects, are significant challenges to long-term adherence.